DARZALEX® SC practical guidance
DARZALEX® SC dosing and treatment schedules
Single-use vial, fixed dose of 1800 mg DARZALEX® and 30000 units of recombinant human hyaluronidase PH20 (ENHANZE® drug delivery technology)[1][2]
- Fixed dose reduces wastage, risk of miscalculating dose and preparation time
- Administration from the first dose of DARZALEX® SC treatment, and from the next scheduled dose in patients who are currently on DARZALEX® IV[1]
- Vials do not require filtration or IV pump[1]
- DARZALEX® solution for injection is a colourless-to-yellow liquid[1]
- Treatment schedules with DARZALEX® SC remain the same, and DARZALEX® SC is available in all approved DARZALEX® IV indications[1]
Quick downloads
SC Checklist beginning of treatment
Includes a first use checklist of Darzalex® SC.
Darzalex® SC Practical Guide
Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more
Glossary
AE: adverse event
IV: intravenous
MOA: mode of action
rHuPH20: recombinant human hyaluronidase
PH20 SC: subcutaneous
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Darzalex®, veja aqui
